Eumelanin-like Poly(levodopa) Nanoscavengers for Inflammation Disease Therapy.
Biomacromolecules
; 25(4): 2563-2573, 2024 Apr 08.
Article
em En
| MEDLINE
| ID: mdl-38485470
ABSTRACT
In the current years, polydopamine nanoparticles (PDA NPs) have been extensively investigated as an eumelanin mimic. However, unlike natural eumelanin, PDA NPs contain no 5,6-dihydroxyindole-2-carboxylic acid (DHICA)-derived units and may be limited in certain intrinsic properties; superior eumelanin-like nanomaterials are still actively being sought. Levodopa (l-DOPA) is a natural eumelanin precursor and expected to convert into DHICA and further remain within the final product through covalent or physical interactions. Herein, poly(levodopa) nanoparticles [P(l-DOPA) NPs] were synthesized with the assistance of zinc oxide as a supplement to synthetic eumelanin. This study found that P(l-DOPA) NPs had â¼90% DHICA-derived subunits on their surface and exhibited superior antioxidant activity compared to PDA NPs due to their looser polymeric microstructure. Benefitting from a stronger ROS scavenging ability, P(l-DOPA) NPs outperformed PDA NPs in treating cellular oxidative stress and acute inflammation. This research opens up new possibilities for the development and application of novel melanin-like materials.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Levodopa
/
Melaninas
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article